Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scinai Immunotherapeutics Ltd ADR (NQ: SCNI )

3.250 +0.230 (+7.62%)
Streaming Delayed Price Updated: 10:53 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Scinai Immunotherapeutics Ltd ADR

< Previous 1 2 3 Next >
New Drug Approach Could Roll Back Pancreatic Cancer Immunotherapy Resistance
Via Investor Brand Network
New Toolkit Launched to Boost Marburg Screening Readiness in the US
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Spotlight Innovative I&I Pipeline and CDMO Services at BIO-Europe 2024
Via Investor Brand Network
Researchers Shine Spotlight on New Barriers to Vaccination
Via Investor Brand Network
Exposures COVID-19
Whooping Cough Prevalence Rises in US as Missed Shots During Pandemic Come Home to Roost
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Schedules Virtual Panel Discussion on Plaque Psoriasis, Its Promising Novel Solution
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast
Via Investor Brand Network
New Approach Could Boost Effectiveness of Immunotherapies Against Colorectal Cancer
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), EIB Close on Loan Restructuring Agreement
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q2 2024 Financial Results, Shares Business Update
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Signs Definitive Loan Restructuring Agreement with EIB Converting Debt into Equity
Via Investor Brand Network
Australia Launches Novel Immunotherapy Program to Help Babies with Peanut Allergies
Via Investor Brand Network
Study Highlights Heightened Risk of Diseases Spreading from Animals to Humans
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives PEI Feedback Regarding Development, Preclinical Trial of Anti-IL-17 NanoAb
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study
Via Investor Brand Network
Study Explores Starving Malignant Cells to Boost Immunotherapy, Improve DNA Damage
Via Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Updated LoI from the European Investment Bank
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q1 2024 Financial Reports, Business Update
Via Investor Brand Network
Study Finds Infectious Diseases Have Surged Post COVID-19 Pandemic
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives LOI with European Investment Bank for Loan-to-Equity Conversion
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Regains Compliance with Nasdaq Listing Rule 5550(a)(2)
Via Investor Brand Network
NIH Researchers Unveil AI Tool to Predict Oncology Patients’ Response to Immunotherapy
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Study Offers Insights on Why Autoimmune Conditions Disproportionately Afflict Women
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases FY 2023 Financial Results, Provides Business Update
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Nasdaq Delisting Notification and Appeal, ADS Ratio Change
Via Investor Brand Network
Vitamin D Could Balance Gut Microbiota, Boost Cancer Immunotherapy
Via Investor Brand Network
Study Finds Presurgery Immunotherapy Safe for Patients with Pancreatic Cancer
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Chief Science Officer to Present at This Month’s Europe Dermatology Drug Development Summit
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana Pharma
Via Investor Brand Network
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.